Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Equity Ratio (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Equity Ratio for 12 consecutive years, with 0.72 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 6.54% to 0.72 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.72, a 6.54% increase, with the full-year FY2025 number at 0.72, up 6.54% from a year prior.
  • Equity Ratio was 0.72 for Q4 2025 at Niagen Bioscience, roughly flat from 0.72 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.72 in Q3 2025 to a low of 0.45 in Q2 2022.
  • A 5-year average of 0.58 and a median of 0.55 in 2021 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: plummeted 30.36% in 2022, then surged 30.4% in 2024.
  • Niagen Bioscience's Equity Ratio stood at 0.55 in 2021, then fell by 3.3% to 0.53 in 2022, then decreased by 2.39% to 0.52 in 2023, then soared by 30.4% to 0.68 in 2024, then rose by 6.54% to 0.72 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Equity Ratio are 0.72 (Q4 2025), 0.72 (Q3 2025), and 0.7 (Q2 2025).